Careers  |  Sign In  |  Register

New Drug for Most Common Breast Cancer Advances Through Clinical Trials

According to Reuters, Ibrance, a breast cancer drug from Pfizer is currently in Phase III clinical trials of a new drug. The drug is designed to treat the most common type of breast cancer, estrogen-receptor positive, human epidermal growth factor receptor 2-negative. Ibrance has been shown to increase the duration of a patient’s life before the cancer worsens, from 3.8 months to 9.2 months. With conditional approval from the FDA for patients who have not previously undergone advanced breast cancer treatment, analysts have estimated that Ibrance could generate annual sales of $5 billion or more.


Read the article published by Reuters.